Additional grant funding under DEVOTE programme
Genedrive awarded £0.2m follow-on grant funding under Innovate UK Innovation Accelerator programme for product enhancements.
- Follow-on grant funding received £0.2m
- Total DEVOTE programme funding approximately £1.2m
Select text to share a quote on X · sign in to keep highlights & notes in your GDR notes
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the extension of the highly successful multi-partner grant award from Innovate UK and the UK Government's Innovation Accelerator programme.
The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") grant, saw the Company benefit from approximately £1.2m through a combination of direct grant income, in-kind partner contributions, and other aligned funding. The DEVOTE programme provided the Company with acute care patient access and supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings. The programme's lead partner, the University of Manchester ("UoM"), has supported the evaluation, validation, and implementation of the Genedrive® CYP2C19 ID Kit.
During the DEVOTE programme the Company completed validation and UKCA certification of the Genedrive® CYP2C19-ID Kit, which was subsequently published in the Journal of Molecular Diagnostics in December 2024 and recommended in final guidance from the UK's National Institute for Health and Care Excellence ("NICE") as the rapid genetics platform of choice for use in the NHS for Clopidogrel genotyping after Ischaemic or Transient Ischaemic Attack.
The significant success of the DEVOTE programme has led to follow-on Innovate UK Innovation Accelerator funding to further progress the DEVOTE project, of which the Company will receive £0.2m directly over the next six months for continuation of implementation of user-led product enhancements which are expected to further improve user experiences in rapid genetic testing environments.
Gino Miele, Chief Executive Officer of genedrive plc, said: "The DEVOTE programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions. The additional non-dilutive grant funding facilitates the mitigation of development costs that would otherwise have been absorbed by the Company."
About DEVOTE
The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme is a collaboration between academics, clinicians, and industry partners. It aims to accelerate the adoption of genomic technology into clinical practice by supporting companies through each aspect of the translational pathway.
Programme information is available at:
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.